Verici presented data from the validation study for Tuteva at the American Transplant Congress last week. As previously indicated, its shows a significantly higher PPV than other tests on the market. Following the publication of this data, preparations are underway for commercial launch later this year, with recruitment for key roles to support this being made. This is another positive milestone on the journey to full commercialisation, with a number of other catalysts expected to follow in the ....
14 Jun 2022
Tuteva data presented at ATC paves way for commercial launch later this year
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Tuteva data presented at ATC paves way for commercial launch later this year
Verici Dx Plc (VRCI:LON) | 9.2 0 0.0% | Mkt Cap: 22.4m
- Published:
14 Jun 2022 -
Author:
Chris Glasper -
Pages:
3
Verici presented data from the validation study for Tuteva at the American Transplant Congress last week. As previously indicated, its shows a significantly higher PPV than other tests on the market. Following the publication of this data, preparations are underway for commercial launch later this year, with recruitment for key roles to support this being made. This is another positive milestone on the journey to full commercialisation, with a number of other catalysts expected to follow in the ....